Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modifying tacrolimus-related toxicity after liver transplantation: Envarsus vs Advagraf
2018-002856-34Phase 4Completed
- Sponsor
- Foundation for Liver Research
- Start
- Oct 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tacrolimus in Hepatic transplant rejection (LTR) (2 arms), sponsored by Foundation for Liver Research. Primary endpoint: Composite primary endpoint of tacrolimus-related toxicity. Started Oct 2018; status: completed.
02
Drugs
tacrolimus
03
Conditions
Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on 2018-002856-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002856-34.